A novel Ad5/11 chimeric oncolytic adenovirus for improved glioma therapy

Li,Xing; Mao,Qinwen; Wang,Dongyang; Xia,Haibin

doi:10.3892/ijo.2012.1674

A novel Ad5/11 chimeric oncolytic adenovirus for improved glioma therapy

Authors:
- Xing Li
- Qinwen Mao
- Dongyang Wang
- Haibin Xia
View Affiliations

Affiliations: Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an 710062, P.R. China, Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
Published online on: October 18, 2012 https://doi.org/10.3892/ijo.2012.1674
Pages: 2159-2165

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effective therapies are needed for malignant glioma patients because of the poor prognosis. Gene therapy combined with virotherapy could be the strategy of choice. In this study, we constructed a modified conditionally replicating adenoviral vector CRAd5/11-Sp-eGFP. The novel vector has the following features: i) the transduction efficiency of CRAd5 was increased using a chimeric fiber 5/11 consisting of an Ad5 tail and an Ad11 shaft and knob; ii) the tumor-specific replication of the vector was improved by utilizing the human survivin promoter to control E1 expression and a poly-A signal inserted right after the inverted terminal repeat (ITR) to stop the non-specific transcriptional activity of the ITR; iii) an expression cassette was inserted into the region between the fiber and E4 region for expressing eGFP. In vitro assays demonstrated that the novel vector could efficiently replicate and kill human glioma cells. Furthermore, CRAd5/11‑Sp-eGFP exhibited significantly increased antitumor effects compared with the control adenoviruses in a xenograft model of glioma. Our results indicate that CRAd5/11-Sp-eGFP represents a promising candidate drug in the treatment of malignant gliomas.

View Figures

View References

1.	Furnari FB, Fenton T, Bachoo RM, et al: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
2.	Grossman SA, Ye X, Piantadosi S, et al: Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 16:2443–2449. 2010. View Article : Google Scholar : PubMed/NCBI
3.	Ulasov IV, Zhu ZB, Tyler MA, et al: Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther. 18:589–602. 2007. View Article : Google Scholar
4.	Chiocca EA, Abbed KM, Tatter S, et al: A phase I open label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther. 10:958–966. 2004. View Article : Google Scholar
5.	Yazaki T, Manz HJ, Rabkin SD and Martuza EL: Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 55:4752–4756. 1995.PubMed/NCBI
6.	Markert JM, Medlock MD, Rabkin SD, et al: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7:867–874. 2000. View Article : Google Scholar : PubMed/NCBI
7.	Sonabend AM, Ulasov IV and Lesniak MS: Gene therapy trials for the treatment of high-grade gliomas. Gene Ther Mol Biol. 11:79–92. 2007.PubMed/NCBI
8.	Sah NK, Khan Z, Khan GJ and Bisen PS: Structural, functional and therapeutic biology of survivin. Cancer Lett. 244:164–171. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ and Loeffler JS: Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol. 20:1063–1068. 2002. View Article : Google Scholar : PubMed/NCBI
10.	Van Houdt WJ, Haviv YS, Lu B, et al: The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg. 104:583–592. 2006.PubMed/NCBI
11.	Ulasov IV, Rivera AA, Sonabend AM, Rivera LB, Wang M, Zhu ZB and Lesniak MS: Comparative evaluation of survivin, midkine, and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol Ther. 6:679–685. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Asaoka K, Tada M, Sawamura Y, Ikeda J and Abe H: Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor. J Neurosurg. 92:1002–1008. 2000. View Article : Google Scholar : PubMed/NCBI
13.	Nandi S, Ulasov IV, Rolle CE, Han Y and Lesniak MS: A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy. J Gene Med. 11:1005–1011. 2009. View Article : Google Scholar : PubMed/NCBI
14.	Segerman A, Atkinson JP, Marttila M, Dennerquist V, Wadell G and Arnberg N: Adenovirus type 11 uses CD46 as a cellular receptor. J Virol. 77:9183–9191. 2003. View Article : Google Scholar : PubMed/NCBI
15.	Gaggar A, Shayakhmetov DM and Lieber A: CD46 is a cellular receptor for group B adenoviruses. Nat Med. 9:1408–1412. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Sirena D, Lilienfeld B, Eisenhut M, et al: The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol. 78:4454–4462. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Fleischli C, Sirena D, Lesage G, Havenga MJ, Cattaneo R, Greber UF and Hemmi S: Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor. J Gen Virol. 88:2925–2934. 2007. View Article : Google Scholar : PubMed/NCBI
18.	Gustafsson DJ, Andersson EK, Hu YL, Marttila M, Lindman K and Strand M: Adenovirus 11p downregulates CD46 early in infection. Virology. 405:474–482. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Zhu ZB, Makhija SK, Lu B, et al: Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and antitumor effects in vitro and in vivo. Int J Oncol. 27:237–246. 2005.PubMed/NCBI
20.	Xia H, Anderson B, Mao Q and Davidson BL: Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. J Virol. 74:11359–11366. 2000. View Article : Google Scholar : PubMed/NCBI
21.	Li X, Liu S, Wang D, Chen H and Xia H: Adenoviral delivered eGFP-intron splicing system for multiple gene RNAi. Biotechnol Lett. 33:1723–1728. 2011. View Article : Google Scholar : PubMed/NCBI
22.	Zhang KJ, Wang YG, Cao X, et al: Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus. Hum Gene Ther. 20:818–830. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Chen W, Wu Y, Liu W, et al: Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma. Cancer Lett. 307:93–103. 2011. View Article : Google Scholar : PubMed/NCBI
24.	Xiao LL, Wu YM, Qian J, et al: The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus. Cancer Biol Ther. 10:242–250. 2010. View Article : Google Scholar : PubMed/NCBI
25.	Bortolanza S, Bunuales M, Otano I, et al: Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther. 17:614–622. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Wohlfahrt ME, Beard BC, Lieber A and Kiem HP: A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res. 67:8783–8790. 2007. View Article : Google Scholar
27.	Zhu ZB, Makhija SK, Lu B, et al: Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther. 11:256–262. 2004. View Article : Google Scholar : PubMed/NCBI
28.	Ulasov IV, Tyler MA, Zhu ZB, Han Y, He TC and Lesniak MS: Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy. Int J Oncol. 34:729–742. 2009.PubMed/NCBI
29.	Fuxe J, Liu L, Malin S, Philipson L, Collins VP and Pettersson RF: Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. Int J Cancer. 103:723–729. 2003. View Article : Google Scholar : PubMed/NCBI
30.	Silver J and Mei YF: Transduction and oncolytic profile of a potent replication-competent adenovirus 11p vector (RCAd11pGFP) in colon carcinoma cells. Plos One. 6:e175322011. View Article : Google Scholar : PubMed/NCBI
31.	Brouwer E, Havenga MJ, Ophorst O, et al: Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. Cancer Gene Ther. 14:211–219. 2007. View Article : Google Scholar : PubMed/NCBI
32.	Wang H, Li ZY, Liu Y, et al: Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med. 17:96–104. 2011. View Article : Google Scholar : PubMed/NCBI
33.	Allen C, McDonald C, Giannini C, Peng KW, Rosales G, Russell SJ and Galanis E: Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas. J Gene Med. 6:1216–1227. 2004. View Article : Google Scholar
34.	Mäenpää A, Junnikkala S, Hakulinen J, Timonen T and Meri S: Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am J Pathol. 148:1139–1152. 1996.